Regulatory & Legal

The crypto exchange touts democratized access to elite investments. But beneath the hype of Pre-IPO tokens lies a world of regulatory risk and unclear ownership.

Facing a 'going concern' warning and collapsing revenue, Splash Beverage Group is ditching drinks for drugs. Its investment in Avicanna is a desperate, yet strategic, pivot.

In an era of AI defense, Bank of America is betting on 2,500 in-person 'Scaminars.' A strategic look at why the future of fraud fighting is surprisingly human.

In a year with the fewest home sales since 2007, one Nevada real estate team didn't just survive; it dominated. Here's how they did it.

As nurses and for-profit homes enter bitter arbitration, the standoff exposes a critical flaw in long-term care: a business model at odds with its mission.

A world-first treatment in Canada saved a young burn victim's face, bypassing devastating grafts. But can this 'miracle' therapy move from one-off to standard care?

Padel is exploding across North America, but its growth depends on quality infrastructure. A new partnership marries local manufacturing with global tech.

Independent tests reveal top cybersecurity tools as malware infiltrates trusted platforms. Are you protected from threats hiding in your creative assets?

After eight years in stealth, an American 3D printing company is challenging the hype-driven tech world with a simple idea: build a reliable product first.

Amid rising cyber threats, Toobit launches a security hub with verifiable Proof of Reserves. But does this bet on transparency truly redefine trust?

With a 269% Bitcoin reserve ratio and a multi-layered defense system, MEXC's latest report signals a new era of verifiable trust and asset protection.

The new YHU Terminal isn't just another airport; it's a calculated move to redefine Montréal's transit map and challenge the future of air travel.

A landmark deal between IQE and Tower Semiconductor not only ends a bitter IP dispute but also secures a vital supply line for the optical chips powering the AI revolution.

Susan Solomon’s Tang Prize is more than an award; it's a tale of how science can save us, and a stark reminder of the irreversible challenges ahead.

The UFC's historic White House event was more than a fight; it was a launchpad for a politically-charged stablecoin, reshaping sports finance and market sentiment.

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

While Nevada's cannabis market contracts, C21 Investments posts record customer growth and an 8% revenue jump, fueled by a high-stakes tax challenge.

Atossa Therapeutics secures a crucial capital lifeline. We dissect the deal, its impact on a promising cancer drug, and what it reveals about biotech funding today.

PM Carney's new food security plan promises affordability and resilience. But can billions in spending truly break the grocery oligopoly and fix our broken chains?

U.S. hospitals waste billions in usable medication each year. A new partnership shows how AI and a digital marketplace can plug the leak, a crucial move in an era of drug shortages.